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This paper investigates the potential for long-term survivorship for young patients diagnosed with Ewing’s sarcoma. Data are
examined from two successive UKCCSG Ewing’s Tumour studies (ET-1 and ET-2). Patients have been followed for up to 20 years.
These studies had suggested that better 5-year survival with ET-2 over the earlier ET-1 was achieved by replacing cyclophosphamide
by ifosfamide and increasing the dose of doxorubicin in a four-drug chemotherapy regimen. The updated hazard ratio, stratified for
metastatic status at diagnosis, of 0.39 (95% confidence interval 0.12–0.61) confirmed the advantage of the ET-2 regimen in terms of
overall survival. Cure models, based on the Weibull distribution, suggested that factors for long-term survival in addition to presence
of metastases were age, primary site of tumour and study. Modelling identified the proportion cured with the ET-2 protocol as best at
70% in those who are under 10 years with a nonpelvic primary site and without metastatic disease. This contrasts to only 13% cure in
those with the corresponding adverse prognostic indicators. Additionally, the risk of death remains greatest but relatively constant
over the first 2 years postdiagnosis, and then declines to a lower but constant value for the next 3 years before reaching the ‘cure
plateau’ at about 5 years. This investigation suggests that ‘cure’ is possible for patients with Ewing’s sarcoma. This is established at
approximately 5 years post diagnosis and the proportion cured depends on the presence of metastases, pelvic site and age at
diagnosis.
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The first UK national Ewing’s Tumour Study (ET-1) commenced
in 1978, following formation of the United Kingdom Children’s
Cancer Study Group (UKCCSG) in 1977. The objectives of the
study were to establish a standard protocol for treatment of
Ewing’s tumour and to document tolerability, toxicity and
complications. At that time, prognosis for patients with Ewing’s
tumour was poor with few patients surviving to 5 years (Nesbit,
1976). However, there was some suggestion that by adding
chemotherapy regimens, utilising vincristine, actinomycin-D,
cyclophosphamide and doxorubicin, with radiotherapy resulted
in improved outcome (Rosen et al, 1974). It had also been
suggested that older age, pelvic site, presence of metastatic disease
and high lactic dehydrogenase (LDH) adversely affect outcome
(Pomeroy and Johnson, 1975).
The nonrandomised and noncomparative ET-1 protocol was
thus designed to utilise the maximum tolerated doses of these four
drugs and radiotherapy in order to maximise their collective
potential. The results of ET-1 were reported with a median follow-
up of 11.2 years and the 5-year overall survival (OS) was 39% (95%
confidence interval (CI) 31–47%) (Craft et al, 1997). The study
concluded that chemotherapy and radiotherapy were indeed
important in the management of Ewing’s sarcoma, but acknowl-
edged that better chemotherapy was needed if more patients were
to survive.
At this time, new information was becoming available on the
prognosis and treatment of patients with this disease (Nesbit et al,
1981; Jurgens et al, 1985). In a review of prognostic factors, the
adverse influence of older age, pelvic site and presence of
metastatic disease was confirmed (Glaubiger et al, 1980; Craft,
1985). In addition, male gender and increasing tumour volume
were identified as possible indicators of poor outcome. Treatment
strategies including doxorubicin (Nesbit et al, 1981), vincristine,
doxorubicin, cyclophosphamide and actinomycin-D (Rosen et al,
1974) and ifosfamide (Demeocq et al, 1984; Bramwell et al, 1985;
Gobel et al, 1986; Magrath et al, 1986) were suggested as regimens
that could result in a higher response rate for patients with Ewing’s
tumour.
The aim of ET-2, albeit also nonrandomised, was to improve
survival over ET-1 by retaining four drugs but replacing cyclopho-
sphamide by ifosfamide and increasing the dose of doxorubicin.
The results of ET-2 were reported, at a median follow-up of
survivors of 4.8 years and gave a 5-year OS of 62% (95% CI 56–
69%) (Craft et al, 1998). It was also noted that the 5-year survival
of metastatic patients had increased from 9% in ET-1 to 23% in
ET-2. As the characteristics of patients in ET-2 were similar to
those of ET-1, it was concluded that the substantial improvement
in survival was real. ET-2 also demonstrated that long-term
survival is achievable in patients with Ewing’s sarcoma and hence
this raises the question of whether it is reasonable to claim ‘cure’
for those who survive beyond a particular time point from
diagnosis.
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lThe objective of this paper is to quantify the changing risk of
patients following their diagnosis and to identify suitable time
points where there are distinct changes in this risk with a view to
identifying those patients who are truly long-term survivors. The
proportion of long-term survivors is estimated using statistical
cure models (CMs) (Sposto, 2002) and we also investigate whether
patient characteristics are prognostic for long-term survival.
In addition, since we are using more complete follow-up data
from both ET-1 and ET-2, an update of the earlier published
reports is given.
MATERIALS AND METHODS
ET-1
ET-1 recruited patients between 1978 and 1986. Induction
chemotherapy commenced with 2.0mgm
 2 (maximum 2.0mg)
vincristine, 50mgm
 2 (maximum 100mg) doxorubicin and
1000mgm
 2 (maximum 1000mg) cyclophosphamide with an
additional 2.0mgm
 2 vincristine on days 8 and 15. At the
discretion of the clinician, a second course was administered
prior to local therapy for patients considered to have a good
response to the first course of chemotherapy. Radiotherapy
commenced at either day 15 or 36, depending on whether one or
two courses of initial chemotherapy was given, and was dependent
on site. Guidelines were 45Gy for long bones to include the whole
bone, 25Gy for rib and 30Gy for pelvic tumours. An additional
boost of 10–15Gy was recommended for all tumours. Doses for
primary tumours of the spine depended on the length of the field,
40Gy were recommended for fields of less than 15cm and 32.5Gy
for longer fields, both given over 3 weeks. Surgery to the primary
site was considered where clinically indicated, dependent on the
site and age of the patient. During radiotherapy, 2.0mgm
 2
vincristine and 400mgm
 2 (maximum 600mg) cyclophosphamide
were given weekly. Following local therapy, chemotherapy with
2.0mgm
 2 vincristine, 50mgm
 2 doxorubicin and 600mgm
 2
cyclophosphamide was alternated every 3 weeks for 2 years with
2.0mgm
 2 vincristine, 1.4mgm
 2 (maximum 2.0mg) actinomy-
cin-D and 600mgm
 2 (maximum 1000mg) cyclophosphamide.
Patients aged less than 40 years of age with previously untreated
biopsy-proven Ewing’s tumour of the bone were eligible. Follow-
up information is collected for 10 years from diagnosis. However,
centres were specifically asked to provide an update on patient
status in August 2002. More complete details of the study have
been given previously (Craft et al, 1997).
ET-2
ET-2 recruited patients between 1987 and 1993. This study utilised
vincristine, 20mgm
 2 doxorubicin and ifosfamide, with actino-
mycin-D to be given when the total tolerable dose of doxorubicin
had been administered. Chemotherapy was administered in three
blocks. The first block consisted of four courses of 9mgm
 2
ifosfamide, 2mgm
 2 vincristine and 60mgm
 2 doxorubicin.
Surgical excision of the primary tumour was then considered for
all patients in an attempt to avoid or minimise use of radiotherapy.
However, radiotherapy was recommended for patients with
residual disease following surgery. For patients with macroscopic
residual disease or for whom surgery was not possible, 55Gy in 30
daily fractions over 6 weeks was recommended. For patients with
microscopic residual disease, 45Gy in 25 daily fractions over 5
weeks was suggested. For patients with lung metastases, whole-
lung irradiation with 15Gy in 10 daily fractions over 2 weeks was
administered, with a local boost of 35Gy in 23 fractions to sites of
bulky disease. Patients also received 2.0mgm
 2 vincristine and
200mgm
 2 cyclophosphamide at weekly intervals during radio-
therapy, although cyclophosphamide was omitted in patients with
pelvic sites. Patients then received three weekly courses of 6gm
 2
ifosfamide, 2mgm
 2 vincristine, 60mgm
 2 doxorubicin followed
by 10 weekly courses of 6gm
 2 ifosfamide, 2mgm
 2 vincristine,
1.5mgm
 2 actinomycin-D. Chemotherapy ceased at 52 weeks
postdiagnosis. Patients aged less than 30 years with previously
untreated biopsy-proven Ewing’s tumour of the bone were eligible.
Follow-up information is collected for 10 years from diagnosis.
However, centres were specifically asked to provide an update on
patient status in August 2002 and again in August 2003. More
complete details of the study have been given previously (Craft
et al, 1998).
Statistical analysis
OS was defined as the time between date of diagnosis and date of
death. Patients alive were censored at the date of last follow-up. OS
was summarised using the Kaplan–Meier method and 95% CIs for
OS at fixed time points were calculated using Greenwood’s formula
(Parmar and Machin, 1995). The difference in OS between ET-1
and ET-2, adjusted for the presence or absence of metastatic
disease at diagnosis using the Cox proportional hazards model,
was summarised by the hazard ratio (HR) and corresponding 95%
CI. Prognostic factors included in the Cox models were based on
those found to be significant in the original analyses (Craft et al,
1997; Craft et al, 1998). Calculations were made using the statistical
procedures in SAS (2001).
Cure models
In situations in which cures are not obtained, the proportion
of patients who remain alive decays with time until all are dead.
One statistical description for their survival is the Weibull model
in which case the proportion alive, W(t), at time t is given by
WðtÞ¼exp½ ðltÞ
g ð 1Þ
where l and g are constants that have to be estimated from the
survival time data. These are termed the scale and shape
parameters, respectively.
However, in circumstances where there may be a cure fraction of
size p, the survival experience may be expressed as
CureðtÞ¼p½1 WðtÞ  ð2Þ
For this model when t¼0, W(0)¼exp[ (l 0)
g]¼1 and so
Cure(0)¼p
[1 W(0)]¼p
0¼1 also. This indicates, as one would
expect, that equations (1) and (2) imply that all are alive at time
t¼0. In contrast, when t¼N, W(N)¼exp[ (l N)
g]¼0 and
so all patients die under equation (1) while Cure(N)¼p
1¼p and
so there are a proportion cured with equation (2).
If the Weibull model has shape parameter g¼1, then equation
(1) becomes
WðtÞ¼exp½ lt ð 3Þ
and this is the exponential model. In this model, l corresponds to
a constant hazard rate. This assumes that a single death rate
applies to each patient irrespective of how long they have survived
from the date of diagnosis. As examples, the survival experience
described by models (1)–(3) is summarised in Figure 1 for l¼1,
g¼2 and p¼0.2.
The ‘cure’ fraction p of equation (2) may depend on the
particular treatment the patient receives as well as upon patient-
specific characteristics such as, for example, the presence or
absence of metastases at diagnosis or their age. This can be
expressed through a regression model for p such as
p ¼ a0 þ a1x1 þ a2x2 þ a3x3 þ   þapxp ð4Þ
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lHere x1, x2,y, xp are the (potentially prognostic) variables and
a0, a1,y, ap the corresponding regression coefficients to be
estimated from the data.
Equation (2) is one form of several CMs described by Sposto
(2002), which allows the possibility that l and g also depend on the
potentially prognostic variables. A more detailed description of
the CMs, together with a computer program that enables the
parameters of such models, including l and g to be fitted, is
available (Sposto, 2002).
Changing hazard
Under the assumption of a Weibull distribution of survival times
of equation (1), it follows that
log½ logWðtÞ  ¼ glogl þ glogðtÞð 5Þ
This is the equation of a straight line with intercept glogl and
slope g. Thus plots of log[ log(Kaplan–Meier estimate of survival
at t)] against log(t) can be used to examine the changing hazard
(risk of death) profile over time (Parmar and Machin, 1995). The
objective was to see if the underlying hazard after a certain time
was much lower than in the immediate post diagnosis period
thereby (perhaps) indicating a ‘cure’ had been achieved for these
patients. Any changes were determined by visual inspection of
these plots.
RESULTS
Patient characteristics and overall survival
Between 1978 and 1986, 142 patients were entered onto the ET-1
study, 22 (15.5%) of whom had metastatic disease. The ET-2 study
recruited 243 patients from 1987 to 1993, with 42 (17.3%) having
metastatic disease. Patient characteristics were similar between the
two studies (Table 1).
For ET-1 the median follow-up time is 17.0 years (range¼0.3–
24.0) and for ET-2 11.1 years (range¼0.5–16.3). In all, 37% of
alive patients have follow-up data of 2002 or later and a further
43% of alive patients have follow-up data of 1999 or later. It is to be
expected that patients are seen in clinic less often as the time from
diagnosis increases. The number of deaths in the two studies by
metastatic status groups are given in Table 2 as are the 5-, 10- and
15-year survival rates. The corresponding OS curves are given in
Figure 2.
For both studies, there is clearly a worse outcome for those
patients with metastases at diagnosis (Figure 2). The correspond-
ing HR of ET-1 vs ET-2, stratified for metastases at diagnosis, is
HR¼0.39 (95% CI 0.12–0.61) (Table 2) and indicates a more
favourable outcome for ET-2 patients.
The fraction ‘cured’
Figure 2 suggests that the CM of equations (3) and (4) should
include as variables the specific study (ET-1 or ET-2) and
the presence or absence of metastases at diagnosis. Table 2
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Figure 1 The proportion surviving with time according to the
exponential, Weibull and cure models for l¼1, g¼2 and p¼0.2.
Table 1 Characteristics of patients with Ewing’s tumour of the bone recruited to ET-1 and ET-2
ET-1 ET-2
Metastatic disease at diagnosis No Yes Total No Yes Total
Gender
Female 53 (37.3%) 15 (10.5%) 68 (47.9%) 87 (35.8%) 18 (7.4%) 105 (43.2%)
Male 67 (47.2%) 7 (5.0%) 74 (52.1%) 114 (46.9%) 24 (9.9%) 138 (56.8%)
Age (years)
Mean 12.3 11.1 12.1 14.0 14.2 14.0
Range 1.8–34.0 4.6–15.4 1.8–34.0 1.9–27.7 1.5–27.0 1.5–27.7
Site
Nonpelvic 97 (68.3%) 16 (11.3%) 113 (79.6%) 163 (67.1%) 31 (12.8%) 194 (79.8%)
Pelvic 23 (16.2%) 6 (4.2%) 29 (20.4%) 38 (15.6%) 11 (4.5%) 49 (20.2%)
Metastases
None 120 (84.5%) 201 (82.7%)
Lung 10 (7.0%) 22 (9.1%)
Bone 7 (4.9%) 10 (4.1%)
Lung and bone 1 (0.7%) 4 (1.6%)
Liver 2 (0.14% —
Nodes 1
a (0.7%) 2
b (0.8%)
Lung and other 1
c (0.7%) 1
d (0.4%)
Bone and other — 2
ef (0.8%)
Lung, bone and other — 1
g (0.4%)
Total 120 22 142 201 42 243
aPara-aortic.
bLymphatic.
cMediastinum.
dFemoral nodes.
eBone marrow, liver and lymph nodes.
fBone marrow, liver and intracranial nodes.
gBone marrow and pleura.
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lsummarises the fit of the CM including these variables. The P-
values for Study and Metastases are both o0.001, indicating a
statistically significant contribution of these variables to the cure
fraction. The corresponding predicted survival curves calculated
from the CM of Table 3 are shown in Figure 3 superimposed on the
Kaplan–Meier estimates.
The shape parameter g¼1.38 of the Weibull distribution is also
statistically significant (P-value o0.001), confirming that this form
of the survival times, rather than the exponential distribution, is
indicated. Adding pelvic site and age to the CM gives the results
corresponding to CM II in Table 3. There is little change in the
estimates corresponding to Study (emphasised in bold within the
table) or Metastases, and the values of the scale and shape
parameters remain essentially unchanged. Nevertheless, the
presence of pelvic disease is an adverse factor (P-value o0.001)
Table 2 CM and Cox regression estimates of survival for study and
presence of metastases at diagnosis
Model Estimate s.e. zP -value
CM I
Intercept 0.090 0.110 0.82 0.415
Study
ET-1 0
ET-2  0.779 0.141  5.52 o0.001
Metastases
No 0
Yes 0.980 0.165 5.95 o0.001
Scale
logl  1.432 0.066  21.86 o0.001
l 0.24
Shape
logg 0.324 0.051 6.42 o0.001
g 1.38
Cox I
Study
ET-1 0
ET-2  0.712 0.142 5.00 o0.001
Metastases
No 0
Yes 0.954 0.164 5.80 o0.001
ET-2 nonmetastatic
ET-1 nonmetastatic
ET-2 metastatic
ET-1 metastatic 0
25
50
75
100
Overall survival (years)
25 20 15 5 01 0
Numbers at risk
ET-1 M   22           3    1        1    1 
ET-1 N  120         52  40      28    8 
ET-2 M   42         15  11        −    − 
ET-2 N  201       135  81      13    − 
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Figure 2 Kaplan–Meier estimates of the survival of patients in studies
ET-1 and ET-2 by presence of metastases at diagnosis.
Table 3 CM and Cox regression estimates of survival for study, presence of
metastases at diagnosis, pelvic involvement and age
Model Estimate s.e. zP -value
CM II
Intercept  0.224 0.168  1.33 0.183
Study
ET-1 0
ET-2  0.809 0.142  5.71 o0.001
Metastases
No 0
Yes 0.878 0.167 5.27 o0.001
Pelvic
No 0
Yes 0.566 0.160 3.55 o0.001
Age X10
No 0
Years
Yes 0.314 0.171 1.84 0.065
Scale
logl  1.448 0.066  21.93 o0.001
l 0.23
Shape
logg 0.330 0.051 6.53 o0.001
g 1.39
CM III
Intercept  0.263 0.175  1.51 0.132
Study
ET-1 0
ET-2  0.904 0.154  5.86 o0.001
Metastases
No 0
Yes 0.875 0.197 4.44 o0.001
Pelvic
No 0
Yes 0.614 0.178 3.45 0.001
Age X10
No 0
Years
Yes 0.426 0.180 2.37 0.018
Scale
Intercept  1.305 0.150  8.72 o0.001
Study
ET-1 0
ET-2 0.267 0.130 2.05 0.041
Metastases
No 0
Yes  0.069 0.244  0.28 0.778
Pelvic
No 0
Yes 0.056 0.177 0.32 0.750
Age X10
No 0
Years
Yes  0.338 0.148  2.28 0.023
Shape
Intercept 0.230 0.121 2.47 0.013
Study
ET-1 0
ET-2 0.135 0.110 1.23 0.218
Metastases
No 0
Yes  0.116 0.175  0.66 0.507
Pelvic
No 0
Yes 0.249 0.172 1.45 0.147
Age X10
No 0
Years
Yes  0.041 0.128  0.32 0.750
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lin establishing cure and there is a suggestion that increasing age
may also have an adverse role (P-value¼0.065).
Adding the prognostic factors to the scale and shape of the CM
gives the results corresponding to CM III in Table 3. This model
suggests that age and study may be significant factors in the scale,
but none of the factors appear to have a significant contribution to
the shape parameter.
Table 4 provides the corresponding estimates of the fraction
cured calculated from CM II. This emphasises the difference in
cure rates observed in the two studies, the influence of metastatic
disease on lowering these rates and the worse outcomes for those
with pelvic involvement and of greater age. Thus, the best cure
fraction of 69.9% is observed in those of ET-2 with nonmetastatic,
nonpelvic sites aged under 10 years, which reduces with this
treatment to 12.6% in those with all the adverse prognostic factors
and to only 1.0% in the corresponding patients in the ET-1 trial.
Table 5 provides the corresponding estimates of the fraction
cured calculated from CM III. Again, this emphasises the
difference in cure rates observed in the two studies, the influence
of metastatic disease on lowering these rates and the worse
outcomes for those with pelvic involvement and of greater age.
However, adding prognostic factors to the scale and shape is seen
to influence the estimates of the fraction cured. For example, the
most extreme difference in the estimate of the fraction cured is
42.5% in CM II compared to 47.4% in CM III for ET-2 patients
aged o10 years with a nonpelvic site and metastatic disease.
However, the difference may be as small as 0.1% as seen for the
ET-1 metastatic patients aged o10 years with a pelvic site.
For comparison purposes, we have included in Tables 2 and 3
the Cox proportional regression models utilising the same
prognostic variables as we have used for the CMs (CMs I–III). It
is clear from these that they too identify the earlier study, presence
of metastases, pelvic involvement and older age as adverse
characteristics with respect to survival time. However, these
models cannot be used to estimate the fraction cured since they
Cox II
Study
ET-1 0
ET-2  0.740 0.143  5.18 o0.001
Metastases
No 0
Yes 0.861 0.166 5.17 o0.001
Pelvic
No 0
Yes 0.540 0.160 3.39 0.0007
Age X10
No 0
Years
Yes 0.297 0.170 1.74 0.0819
Table 3 (Continued)
Model Estimate s.e. zP -value
ET-1 nonmetastatic  
ET-1 metastatic  
ET-2 nonmetastatic  
ET-2 metastatic  
Predicted Observed
0
25
50
75
100
Overall survival (years)
25 20 15 5 01 0
Predicted Observed
Overall survival (years)
25 20 15 5 01 0
Predicted Observed
Overall survival (years)
25 20 15 5 01 0
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Figure 3 Kaplan–Meier estimates of the survival of patients in studies ET-1 and ET-2 by presence of metastases at diagnosis with the corresponding fitted
CMs of Table 3.
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ldo not plateau, but behave in a similar way to the exponential and
Weibull models of Figure 1.
Establishing time to cure
The log[ log(survival)] plots for both ET-1 and ET-2 (Figure 4)
emphasise the improved survival with ET-2 and suggest that the
hazards are approximately proportional in that the curves are
essentially parallel. However, for both studies, there is an apparent
decrease in the cumulative hazard rate at around 2 years and a
further small decrease at around 5 years. This suggests a complex
picture – an almost constant death rate postdiagnosis until
approximately 2 years, a reduced but again near-constant death
rate for the next 3 years and then a fall to the corresponding
‘plateau’. Although the CM does not require a formal definition of
the time at which a long-term survivor can be considered as a cure,
it is useful to have an indication of what may be considered as
appropriate for this. On this basis, ‘cure’ is identified as survival
beyond 5 years from diagnosis.
DISCUSSION
The additional extra 5.8 years of follow-up for ET-1 and 6.3 years
for ET-2 following publication of these studies (Craft et al, 1997,
1998) confirm the estimate of the overall 5-year survival of ET-1 as
39% and marginally increase that for ET-2 by 2%–64% (95% CI
58–70%). The HR, estimated using the Cox proportional hazards
model adjusted for the presence of metastases at diagnosis, in
favour of ET-2 is 0.39 (95% CI 0.12–0.61) and suggests a clear
advantage to the newer regimen, although it is acknowledged that
this is estimated from two successive (in time) studies and not
from a randomised controlled trial of the two options. As such, this
favourable outcome must be interpreted cautiously as there are
many factors that could account for this improvement in survival.
Although there is a strong possibility that the change in the
chemotherapy between ET-1 and ET-2 did indeed contribute to the
increase in survival, it must also be noted that the trials cover a
large time interval (1978–1986 for ET-1, 1987–1993 for ET-2) and
thus other factors may account for the apparent difference in
survival between the two treatment regimens. For example, due to
improved diagnostic techniques, patients may present with less
advanced metastatic disease in ET-2 compared to ET-1. Changes in
methods of local control may also have made a contribution. For
example, in ET-2, patients with lung metastases were treated with
whole-lung irradiation and this is likely to have contributed to the
improved survival. Also, response to chemotherapy is now
considered as an important prognostic factor, particularly in
patients with localised disease. Early studies, such as ET-1 and ET-
2, did not collect data relating to response, and thus it is difficult to
assess whether improved survival is due to more patients showing
a good response to the ET-2 chemotherapy regimen compared to
ET-1. Therefore, although the enhancement in survival of ET-2
over ET-1 appears to be real, it is not possible to identify or
quantify the precise reasons for improvement. This highlights the
need to conduct randomised controlled trials, and this policy has
been reflected in the third Ewing’s sarcoma trial (EICESS 92)
involving a wide European collaboration.
Despite the additional follow-up, there have been very few
further ‘first’ relapses and/or deaths beyond those reported earlier.
This suggests that ‘first’ events or deaths, from the Ewings’ tumour
itself, more than 5 years from diagnosis are rare. However, it
should be recognised that neither study requested clinical
information on any patient beyond 10 years from diagnosis; so it
Table 4 Estimated fraction cured (%) with 95% CIs by study, presence of
metastasis at diagnosis, pelvic involvement and age
ET-1 ET-2
Metastatic Metastatic
Pelvis
involved
Age
(years) No Yes No Yes
No o10 45.0 14.6 70.1 42.5
(32.9–6.3) (2.5–36.9) (52.0–82.4) (11.3–71.5)
X10 33.5 7.2 61.4 31.0
(11.9–
56.9)
(0.0–37.6) (28.7–82.7) (1.6–71.9)
Yes o10 24.5 3.4 53.4 22.2
(6.9–47.7) (0.0–27.7) (20.8–77.9) (0.0–64.9)
X10 14.6 1.0 42.4 12.7
(0.0–48.4) (0.0–28.4) (4.9–78.3) (0.0–65.4)
Table 5 Estimated fraction cured (%) with 95% CIs by study, presence of
metastasis at diagnosis, pelvic involvement and age, with these factors
included in the scale and shape
ET-1 ET-2
Metastatic Metastatic
Pelvis
involved
Age
(years) No Yes No Yes
No o10 46.4 15.8 73.2 47.4
(33.9–58.0) (2.2–41.1) (55.2–84.9) (12.3–76.6)
X10 30.8 6.0 62.1 31.9
(9.5–55.6) (0.0–38.4) (27.5–83.9) (1.1–75.1)
Yes o10 24.2 3.3 56.2 25.1
(5.9–49.1) (0.0–31.3) (21.1–80.8) (0.4–70.6)
X10 11.4 0.5 41.4 12.1
(0.2–46.5) (0.0–28.7) (3.4–79.5) (0.0–68.8)
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Figure 4 The log[ log(survival proportion)] against log(survival time)
for studies ET-1 and ET-2 and by presence or absence of metastases at
diagnosis.
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lis possible that some relapses have gone unrecorded. Clearly, as
time elapses, those patients remaining alive will approach the age-
specific death rates of their contemporaries and so non-Ewings’
sarcoma-related deaths may occur. In the young, road traffic
accidents are a major cause. However, since the mortality of young
patients is relatively small, their survival curve will appear as a
‘plateau’ for a number of years, followed by an eventual decline
with increasing age. Once the decline commences, it will no longer
be sensible to estimate a ‘cure’ fraction. Our analysis suggests that
the risk of death is highest following diagnosis and remains
constant for approximately 2 years, declines thereafter but again
remains constant for 3 more years, and finally declines to a death
rate consistent with cure.
In general, it is inadvisable to regard a plateau (such as those of
Figure 2) as firm evidence that patients have been ‘cured’, since the
level is unreliable unless a relatively large number of patients are
still alive, and being followed up, for a survival duration
considerably greater than the time at which this plateau begins
(Peto et al, 1977). However, the CMs (Sposto, 2002) do permit a
cure fraction to be estimated and also allow patient- and disease-
specific factors prognostic for this fraction to be determined.
Prognostic factors established for the cure fraction act indepen-
dently of any effect they may have on early outcome.
Mixture models for cure have been proposed (Jones et al, 1981),
which assume patients are either cured by treatment, that is, the
disease is eradicated, or they are not, and only the latter would
experience a recurrence after some time. However, Sposto (2002)
argues that with combined modality treatment of long duration,
this division into ‘eradicated’ and ‘not-eradicated’ at a relatively
early stage postdiagnosis does not readily apply, since eradication
of the disease, if it occurs, can occur at any time during the
extended course of treatment. Although it is not necessarily always
the case, the Cox models for the Ewing’s tumour studies
considered here identify the same factors as prognostic for
survival time as do the CMs for ‘cure’. The CM is particularly
likely to identify different prognostic factors to the Cox model
where the nonproportional hazards are displayed between prog-
nostic groups. Also, Cox models can only provide a satisfactory
description of relative survival of the various groups in the earlier
years following commencement of treatment, as they cannot
plateau.
The Sposto (2002) CM includes the possibility that both the
values of the scale and shape parameters depend on prognostic
factors. Indeed, we noted in one subgroup (ET-2 metastatic
patients less than 10 years with no pelvic involvement) that the
estimate of the fraction cured was raised by as much as 4.9% when
prognostic factors were included for the scale and shape
parameters as well as for the cure fraction itself. Clearly, if firmly
established, a potential difference in cure rates of this magnitude is
clinically important and this emphasises the need to select the
most appropriate model.
Although we have used and indeed estimated the proportion
cured, the very term ‘cure’ in this context needs to be carefully
examined as it is well recognised that these patients are at
increased risk of developing a second malignancy and late toxic
effects both of which may increase their risk of mortality. One
possibility is to define cure in terms of event-free survival rather
than merely survival alone, but to establish this it would require
(perhaps unacceptable) detailed monitoring of patients for a very
extended period.
In conclusion, we have established in these young patients with
Ewings’ sarcoma that the treatment regimen (in our case, ET-1 and
ET-2), presence or absence of metastases, pelvic involvement and
age are all indicative of the fraction eventually cured. We estimate
that the cure fraction can range from as little as 1 to 70%
dependent on regimen, patient- and disease-specific character-
istics. There is also a suggestion (Table 4) that the ET-2 regimen
has not only increased the cure fractions but has also reduced the
proportionate gap in the cure fraction between metastatic and
nonmetastatic patients from approximately 1/4 to 1/2 in the four
pelvis involved by age groups. As survival rates continue to
improve, long-term survival and cure are becoming increasingly
important end points when planning clinical trials in patients with
Ewing’s sarcoma.
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